Misconceptions about HIV/AIDS

Global HIV Treatment Markets, Epidemiology and Patient Flow Report 2020-2035 - Focus on US, Germany, France, Italy, Spain, UK, Japan, G7 Countries - ResearchAndMarkets.com

Retrieved on: 
Friday, May 14, 2021

b'The "Global HIV Treatment Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal HIV Treatment Epidemiology and Patient Flow Analysis - 2021, provides HIV Treatment epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global HIV Treatment Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal HIV Treatment Epidemiology and Patient Flow Analysis - 2021, provides HIV Treatment epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize HIV Treatment patients, history of the disease at the population level (HIV Treatment prevalence, HIV Treatment incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: HIV Treatment patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for HIV Treatment market sizing, assessing market potential, and developing drug forecast models\nIdentify HIV Treatment patients segments through age groups, gender, and disease sub-types\nEvaluate HIV Treatment market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005178/en/\n'

Medisafe recognizes World AIDS Day with Top HIV/AIDS app

Retrieved on: 
Tuesday, December 1, 2020

Today, Apple featured Medisafe on the Today tab on the App Store as part of its campaign for World AIDS Day.1 in 7 Americans are living with HIV/AIDS, many of which are managing multiple medications without proper guidance.

Key Points: 
  • Today, Apple featured Medisafe on the Today tab on the App Store as part of its campaign for World AIDS Day.1 in 7 Americans are living with HIV/AIDS, many of which are managing multiple medications without proper guidance.
  • "Medisafe continues to support patients living with chronic conditions serving as an essential tool in the lives of millions of patients, including those who continue to live with HIV/AIDS," said Medisafe CEO Omri Shor.
  • "On this World AIDS Day, we look toward future advancements in technology that can help reduce the fear of living with HIV/AIDS as we also hope for the day when a cure is discovered, and we can put an end to the virus."
  • Medisafe is the leading evidence-based digital therapeutics company providing medication management solutions across the healthcare continuum, a $300 billion problem in the US alone.

Enochian Biosciences Announces Three Scientific Presentations on Potential HIV and HBV Cures

Retrieved on: 
Wednesday, May 13, 2020

Two presentations provide the first description of a novel approach to potentially cure HIV.

Key Points: 
  • Two presentations provide the first description of a novel approach to potentially cure HIV.
  • Two people the London Patient and the Berlin Patient have been cured of HIV following transplantation of cells with genetic mutations that prevent HIV infection.
  • Currently, we have good oral, safe and effective therapies that patients with HIV or chronic HBV must take daily, for life.
  • Non-compliance can lead to HIV and HBV viral resistance or to acute liver flares in patients with chronic liver disease.

Institute of Human Virology and OncoImmune Launch Clinical Trial to Lessen Effects of HIV Later in Infection

Retrieved on: 
Monday, February 24, 2020

This is intended for use in HIV patients who have been receiving the traditional antiretroviral therapies that control, but do not cure, HIV infection.

Key Points: 
  • This is intended for use in HIV patients who have been receiving the traditional antiretroviral therapies that control, but do not cure, HIV infection.
  • The new trial will test the drug for its ability to tone down chronic inflammation and metabolic abnormalities in HIV patients.
  • The trial is supported by a grant from the National Heart, Lung and Blood Institute.
  • Therefore, it holds the promise to reduce many health risks imposed by HIV infection, including heart and liver diseases.

2019 Research Report on HIV: Discussion on Etiology, Pathophysiology, Disease Classification and Staging Systems, Epidemiology, and Marketed Therapies - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 13, 2020

The "HIV: First-in-Class Therapies Target Major Unmet Needs Including Drug Resistance and Latency Reversal" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HIV: First-in-Class Therapies Target Major Unmet Needs Including Drug Resistance and Latency Reversal" report has been added to ResearchAndMarkets.com's offering.
  • Without treatment, HIV can progress to AIDS and may be fatal within a number of years.
  • As the disease progresses, the virus causes depletion of a type of immune cell known as cluster of differentiation 4 (CD4) cells in the infected host.
  • Understand the current disease landscape with an in-depth discussion of etiology, pathophysiology, disease classification and staging systems, epidemiology, and marketed therapies for HIV.

CytoDyn Abstract by Dr. Jonah Sacha for Use of Leronlimab as PrEP is Accepted by the Keystone Symposia on HIV Pathogenesis and Cure

Retrieved on: 
Monday, January 27, 2020

The scientific premise for leronlimab-based PrEP is founded on the long-standing observation that CCR5-deficient individuals are extremely resistant to HIV infection.

Key Points: 
  • The scientific premise for leronlimab-based PrEP is founded on the long-standing observation that CCR5-deficient individuals are extremely resistant to HIV infection.
  • The results presented here demonstrate that leronlimab treatment is able to prevent sexual transmission of HIV.
  • Over the past 15 years, HIV therapies have advanced significantly, however, there has been minimal prevention of HIV in the U.S.
  • According to the CDC (Centers for Disease Control and Prevention), about 38,000 new infections occur annually the in U.S. alone.

HIV-Positive New Yorkers Are Living Longer but Still Dying of Underlying Infection, Not Just from Old Age

Retrieved on: 
Wednesday, August 28, 2019

The infectious disease is known for drastically lowering the body's immune defenses and is spread by the human immunodeficiency virus, or HIV.

Key Points: 
  • The infectious disease is known for drastically lowering the body's immune defenses and is spread by the human immunodeficiency virus, or HIV.
  • "Even a treated HIV-positive patient is immunocompromised and at increased risk of dying from pneumonia," says Rapkiewicz.
  • Experts estimate that more than 100,000 New Yorkers have died of AIDS-related causes since the epidemic began, and 125,000 are currently living with HIV.
  • NYU Langone study co-investigators included Robert Holzman, MD, who has treated people living with HIV in New York since the beginning of the epidemic.

CytoDyn Provides Update on Dose Escalating Trial with Leronlimab for HIV Monotherapy for a Potential Pivotal Trial

Retrieved on: 
Wednesday, August 14, 2019

The U.S. Food and Drug Administration (FDA) has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases.

Key Points: 
  • The U.S. Food and Drug Administration (FDA) has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases.
  • The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer (mTNBC).
  • Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab can significantly reduce or control HIV viral load in humans.
  • CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients.